APA (7th ed.) Citation

M, H., H, F., A, G., A, B., E, K., A, N., & M, F. (2022). Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial. Journal of medical virology, 94(7), 3184. https://doi.org/10.1002/jmv.27724

Chicago Style (17th ed.) Citation

M, Hassaniazad, Farshidi H, Gharibzadeh A, Bazram A, Khalili E, Noormandi A, and Fathalipour M. "Efficacy and Safety of Favipiravir Plus Interferon-beta Versus Lopinavir/ritonavir Plus Interferon-beta in Moderately Ill Patients with COVID-19: A Randomized Clinical Trial." Journal of Medical Virology 94, no. 7 (2022): 3184. https://doi.org/10.1002/jmv.27724.

MLA (9th ed.) Citation

M, Hassaniazad, et al. "Efficacy and Safety of Favipiravir Plus Interferon-beta Versus Lopinavir/ritonavir Plus Interferon-beta in Moderately Ill Patients with COVID-19: A Randomized Clinical Trial." Journal of Medical Virology, vol. 94, no. 7, 2022, p. 3184, https://doi.org/10.1002/jmv.27724.